NervGen Pharma Hosts Virtual Investor Event for Stakeholders
NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a groundbreaking biotech company specializing in neurorestorative therapeutics, has announced an upcoming virtual investor event set for April 9. This event is designed to enhance engagement with stakeholders and provide valuable insights into the company’s initiatives and advancements in spinal cord injury treatments.
Insights from Industry Leaders
The event will feature esteemed guests, including Monica Perez, PT, Ph.D., from the Shirley Ryan AbilityLab, and Steven Kirshblum, MD, from Rutgers New Jersey Medical School. Both experts will join NervGen's management team to discuss crucial medical needs and current treatments available for spinal cord injury patients.
Highlighting Groundbreaking Clinical Trials
With the anticipation of clinical data expected soon regarding its Phase 1b/2a proof-of-concept trial, NervGen aims to provide participants with comprehensive insights into the study’s design and objectives. This includes a focus on electrophysiological endpoints, showcasing how NVG-291—NervGen’s leading bioactive peptide—demonstrates promise in treating spinal cord injuries.
Preclinical Trial Updates and Q&A Session
Participants can look forward to updates on preclinical trials involving NVG-291-R, a rodent prototype that illustrates impressive outcomes in recovery and repair processes. A live Q&A session will provide an interactive platform for attendees to ask questions and engage directly with company representatives.
About the Distinguished Speakers
Monica A. Perez, PT, PhD
Dr. Perez holds the position of Scientific Chair at the Arms + Hands Lab and serves as a professor at Northwestern University. With over 15 years of experience in studying neural mechanisms, she is committed to developing innovative rehabilitation protocols for spinal cord injury patients, focusing on understanding voluntary movement control.
Steven Kirshblum, MD
Dr. Kirshblum is the Professor and Chair at Rutgers New Jersey Medical School. His expertise in spinal cord injury leads him to serve as the program director for the Spinal Cord Injury Medicine Fellowship and as Chief Medical Officer for the Kessler Foundation.
Understanding the Phase 1b/2a Trial
The Phase 1b/2a clinical trial investigates NVG-291's safety and effectiveness in two groups—those with chronic and subacute spinal cord injuries. This meticulous study aims to demonstrate clinical improvements primarily through enhanced motor function and strength, utilizing innovative measures like electrophysiological assessments and MRI imaging to track recovery progress.
Innovations in Neurorestorative Therapies
NervGen’s commitment to developing and delivering cutting-edge neurorestorative therapies underpins its operations. The recent licensing of NVG-291 from Case Western Reserve University reflects the substantial preclinical evidence supporting its efficacy. NVG-291 has received Fast Track designation, marking it as a pivotal advancement in treating spinal injuries.
NervGen’s Future Prospects
As a clinical-stage biotech entity, NervGen Pharma is not resting on its laurels; prospective developments also include NVG-300—a candidate aimed at addressing issues related to ischemic stroke and ALS. The forthcoming trial results and innovative research position NervGen as a leader in neurological therapeutics.
Contact Information
For inquiries, please reach out to:
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
617.308.4306
Frequently Asked Questions
What is NervGen Pharma's main focus?
NervGen Pharma focuses on developing advanced neurorestorative therapies for treating spinal cord injuries and other neurological conditions.
When is the virtual investor event scheduled?
The virtual investor event is set for April 9, providing stakeholders an opportunity to learn about NervGen's latest advancements.
Who are the featured speakers at the event?
Monica Perez, PT, Ph.D., and Steven Kirshblum, MD, will present alongside NervGen's management team to discuss relevant research and treatment methodologies.
What trial phase is NervGen currently in for NVG-291?
NervGen is currently conducting a Phase 1b/2a trial to assess the safety and efficacy of NVG-291 in spinal cord injury contexts.
What is the significance of NVG-291?
NVG-291 is emerging as a first-in-class therapeutic peptide targeting nervous system repair, with potential applications in multiple neurological conditions.
